It occurs to me that if the DCVax-L trial meets its primary endpoint for PFS in the phase III trial, it might be the current phase II adjuvant(s) versus no adjuvant, 60 patient enrolled trial at UCLA that could be expanded (internationally) and used as a confirmatory trial because it does not have a crossover. I've speculated before it might be used as a confirmation trial, but I probably forgot to consider it might be expanded. I also have been ruminating on whether the current phase III trial would even release its OS numbers when it releases its PFS results if it meets its primary endpoint, because that will not be judged until 233 OS events anyway (which may never happen within the trial's timeframe). This may seem like a slight variation on what I thought might occur under a scenario, but by expanding the current adjuvant trial enrollment, it could avoid the potential crossover confoundment that Dr. Liau addressed in mid October. This also might allow countries to ramp at a more comfortable pace.
Of course, none of this may be necessary depending on the results in the two trials, but it is something that might be on the table as another possible scenario.
Market Data 
Markets 
AI
